1. Home
  2. CBIO vs AVD Comparison

CBIO vs AVD Comparison

Compare CBIO & AVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBIO
  • AVD
  • Stock Information
  • Founded
  • CBIO 2003
  • AVD 1969
  • Country
  • CBIO United States
  • AVD United States
  • Employees
  • CBIO N/A
  • AVD N/A
  • Industry
  • CBIO
  • AVD Agricultural Chemicals
  • Sector
  • CBIO
  • AVD Industrials
  • Exchange
  • CBIO Nasdaq
  • AVD Nasdaq
  • Market Cap
  • CBIO 173.5M
  • AVD 163.2M
  • IPO Year
  • CBIO N/A
  • AVD N/A
  • Fundamental
  • Price
  • CBIO $10.13
  • AVD $5.11
  • Analyst Decision
  • CBIO Strong Buy
  • AVD Strong Buy
  • Analyst Count
  • CBIO 5
  • AVD 1
  • Target Price
  • CBIO $25.60
  • AVD $12.00
  • AVG Volume (30 Days)
  • CBIO 127.5K
  • AVD 173.0K
  • Earning Date
  • CBIO 11-23-2025
  • AVD 11-10-2025
  • Dividend Yield
  • CBIO N/A
  • AVD N/A
  • EPS Growth
  • CBIO N/A
  • AVD N/A
  • EPS
  • CBIO N/A
  • AVD N/A
  • Revenue
  • CBIO N/A
  • AVD $529,067,000.00
  • Revenue This Year
  • CBIO N/A
  • AVD N/A
  • Revenue Next Year
  • CBIO N/A
  • AVD $3.54
  • P/E Ratio
  • CBIO N/A
  • AVD N/A
  • Revenue Growth
  • CBIO N/A
  • AVD N/A
  • 52 Week Low
  • CBIO $10.13
  • AVD $3.28
  • 52 Week High
  • CBIO $21.40
  • AVD $6.68
  • Technical
  • Relative Strength Index (RSI)
  • CBIO 31.99
  • AVD 41.66
  • Support Level
  • CBIO $10.96
  • AVD $4.94
  • Resistance Level
  • CBIO $12.58
  • AVD $5.28
  • Average True Range (ATR)
  • CBIO 0.74
  • AVD 0.25
  • MACD
  • CBIO -0.10
  • AVD -0.09
  • Stochastic Oscillator
  • CBIO 4.27
  • AVD 10.20

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About AVD American Vanguard Corporation ($0.10 Par Value)

American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.

Share on Social Networks: